ohm: Dec29 marks 14 days since full enrollment, and 14 days is the CD12 timeline for several secondary endpoints related to mortality. Given the label extension, wouldn't all the patients still on the 42 day trial treadmill demand to receive LL under the label extension to down risk the1/3rd possibility that they have been receiving the placebo. Accordingly, does it make sense the FDA/DSMC might unblind on Dec29 to check if the 14 day mortality endpoints have been met, and, if so, switch all the placebo patients to LL in anticipation of full approval based on success in meeting the more difficult 14 day mortality endpoints?